Nektar Therapeutics stockholders approve all proposals at 2023 annual meeting

Proposal 3 The proposal to ratify the appointment, by the audit committee of the Board, of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023 was approved with the following votes. For Against Abstain Broker Non-Votes 152,198,308 3,794,659 287,072 0

Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the “Board”) until the Company’s 2026 Annual Meeting of Stockholders. Nominee For Against Abstain Broker Non-Votes Myriam J. Curet 86,013,697 48,360,669 263,246 21,642,427 Howard W. Robin 131,440,338 2,940,207 257,067 21,642,427

Proposal 5 The proposal to vote on the frequency with which the Company’s stockholders will be provided a vote, on a non-binding advisory basis, on the compensation of the Company’s Named Executive Officers, received the following votes: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 131,842,535 91,293 2,367,608 336,176 21,642,427

Proposal 4 The proposal to approve the compensation of the Company’s Named Executive Officers, on a non-binding advisory basis, was approved with the following votes. For Against Abstain Broker Non-Votes 114,458,620 19,391,723 787,269 21,642,427

Proposal 2 The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 12,000,000 shares was approved with the following votes. For Against Abstain Broker Non-Votes 128,177,858 6,147,762 311,992 21,642,427